"Reform for better investment" says CBI ahead of Darzi NHS review
This article was originally published in Clinica
Executive Summary
"One thing recent years have shown us is that extra money alone has a limited effect on service outcomes." This is among the views with which the UK's Confederation of British Industry (CBI) has paved the way for the "next stage" review of the NHS, which due to be unveiled as Clinica's daily service went out today.
You may also be interested in...
Darzi Takes Witty's Seat At UK Innovation Group, As Brexit Heats Up And NHS Adds Ambiguity
The UK's Accelerated Access Collaborative (AAC) has filled the hole left by ex-Glaxo CEO Andrew Witty's recent departure with public-sector stalwart Lord Ara Darzi. This should restore some certainty to the initiative when the UK health-care sector was thrown into confusion by the promise of £20bn more NHS funding and by ongoing Brexit machinations with uncertain impact.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.